Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Harmony Biosciences Holdings Inc
(NQ:
HRMY
)
34.60
-0.17 (-0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Harmony Biosciences Holdings Inc
< Previous
1
2
3
4
5
6
Next >
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
October 02, 2024
Via
Benzinga
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
September 10, 2024
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.
Via
Benzinga
Unveiling 6 Analyst Insights On Harmony Biosciences
September 10, 2024
Via
Benzinga
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
August 06, 2024
HRMY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Analyst Expectations For Harmony Biosciences's Future
August 06, 2024
Via
Benzinga
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
June 21, 2024
Via
Benzinga
Key Takeaways From Harmony Biosciences Analyst Ratings
April 30, 2024
Via
Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
March 28, 2024
Via
Benzinga
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
May 14, 2024
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
April 30, 2024
HRMY earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Analyst Ratings For Harmony Biosciences
February 22, 2024
Via
Benzinga
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
January 10, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.
Via
Chartmill
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts
January 02, 2024
Via
Benzinga
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
April 30, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
April 30, 2024
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with...
Via
Benzinga
Topics
Earnings
Exposures
Financial
Updates: HRMY, MELI, SWAV
February 28, 2024
Another day, another slew of quarterly update reports for our followed stocks.
Via
Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
February 22, 2024
HRMY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
February 12, 2024
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.
Via
InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
February 07, 2024
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks.
Via
InvestorPlace
NASDAQ:HRMY: good value for what you're paying.
January 25, 2024
In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.
January 03, 2024
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Why Harmony Biosciences Stock Got Slammed Today
January 02, 2024
The commercial-stage company was dinged by a bearish new take from a researcher.
Via
The Motley Fool
2023 Year In Review
January 02, 2024
The S&P 500 had a strong year in 2023, returning about 24% to investors from the beginning of the year to the end. Some of that was a bounce back from a poor 2022 when it was down over 11%.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
NASDAQ:HRMY is showing good growth, while it is not too expensive.
December 18, 2023
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
NASDAQ:HRMY, an undervalued stock with good fundamentals.
December 13, 2023
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.